REIN THERAPEUTICS INC
RNTX · NASDAQ
Updated at 2026-10-14 09:20:46
- Today's High
- $0.77
- Today’s Low
- $0.75
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.77
- Previous Close
- $0.78
- Volume
- 108.13K
- Market Cap
- $67.71M
- P/E Ratio
- --
- EPS
- $-1.59
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 12407 N. MOPAC EXPY., AUSTIN, TX, UNITED STATES, 78758
- Country
- US
- Listing Date
- 2017-06-29
- Fiscal Year End
- December
- Shares Outstanding
- 85.54M
- CIK
- 0001420565
- Website
- www.reintx.com
Rein Therapeutics Inc (RNTX) is a forward-thinking biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative disorders through its proprietary technology platform that merges advanced neuroscience with drug development. With a robust pipeline aimed at addressing critical unmet medical needs, the company is positioned at the forefront of a rapidly evolving therapeutic landscape. Led by an experienced management team with a proven track record in the industry, Rein Therapeutics offers institutional investors a compelling opportunity to engage with transformative healthcare solutions that have the potential to drive significant patient impact and market growth.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$6.07M
2026-03-31
$5.23M
2025-12-31
$3.95M
2025-09-30
$5.49M
Net Income
2026-06-30
-$6.37M
2026-03-31
-$5.83M
2025-12-31
-$31.96M
2025-09-30
-$5.58M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.10
2026-03-31
$-0.19
2025-12-31
$-1.22
2025-09-30
$-0.21
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$6.37M
2026-03-31
-$5.21M
2025-12-31
-$3.87M
2025-09-30
-$5.58M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
2.17%
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $6.07M | $5.23M | $3.95M | $5.49M |
| Net Income | -$6.37M | -$5.83M | -$31.96M | -$5.58M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.10 | $-0.19 | $-1.22 | $-0.21 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$6.37M | -$5.21M | -$3.87M | -$5.58M |
| Effective Tax Rate | -- | -- | 2.17% | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.